Amgen is set to release its second-quarter earnings next month, and analysts are projecting modest single-digit growth in ...

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of ...

Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

Amgen combines patent protection, a robust pipeline, and strong execution for defensive investment. Click here to read an ...

Amgen (AMGN) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Amgen Inc. closed 14.87% below its 52-week high of $346.85, which the company reached on July 25th.

Amgen Inc. closed 13.40% below its 52-week high of $346.85, which the company achieved on July 25th.

Amgen plans to proceed with Phase 3 trials, initiating patients on a lower dosage that will gradually increase over an eight-week period.

Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like vomiting, according to mid-stage trial results presented at a medical meeting ...

Biocon failed to provide critical information about proposed denosumab product, Amgen claims | Company expects ‘sales erosion ...

Amgen said on Monday its experimental therapy helped patients with advanced gastric cancer live longer when combined with ...